Abstract
Umbilical cord blood transplantation from HLA-identical siblings provides good results in children. These results support targeted efforts to bank family cord blood units that can be used for a sibling diagnosed with a disease curable by allogeneic hematopoietic stem cell transplantation or for research that investigates the use of allogeneic or autologous cord blood cells. Over 500 patients transplanted with related cord blood units have been reported to the Eurocord registry with a 4-year overall survival of 91% for patients with nonmalignant diseases and 56% for patients with malignant diseases. Main hematological indications in children are leukemia, hemoglobinopathies or inherited hematological, immunological or metabolic disorders. However, family-directed cord blood banking is not widely promoted, many cord blood units used in sibling transplantation have been obtained in private banks that do not meet the necessary criteria needed to store these units. Marketing by private banks who predominantly store autologous cord blood units leads to public confusion. There are very few current validated indications for autologous storage but some new indications might appear in the future. Little effort is devoted to provide unbiased information and education to allow for the distinction between the different types of banking, economic models and standards involved by such programs. In order to provide a better service for families in need, directed-family cord blood banking activities should be encouraged and closely monitored with common standards and better information on current and future indications. . b  y  t  h  e  p  r  i  v  a  t  e  s  e  c  t  o  r  ,  t  o  f  a  m  i  l  i  e  s  f  o  r  p  r  i  v  a  t  e  C  B  c  o  l  l  e  c  t  i  o  n  a  n  d  s  t  o  r  a  g  e  w  i  t  h  o  u  t  a  n  y  c  u  r  r  e  n  t  t  h  e  r  a  p  e  u  t  i  c  p  u  r  p  o  s  e  a  n  d  f  o  r  p  o  t  e  n  t  i  a  l  u  s  e  b  y  t  h  e  d  o  n  o  r  l  a  t  e  r  i  n  l  i  f  e  .  A  C  B  b  a  n  k  e  d  i  n  t  h  i  s  m  a  n  n  e  r  m  a  y  o  c  c  a  s  i  o  n  a  l  l  y  b  e  n  e  f  i  t  a  s  i  b  l  i  n  g  .  W  h  e  r  e  a  s  f  a  m  i  l  y  -d  i  r  e  c  t  e  d  b  a  n  k  i  n  g  f  o  r  a  l  l  o  g  e  n  e  i  c  p  u  r  p  o  s  e  s  d  o  e  s  n  o  t  r  a  i  s  e  e  t  h  i  c  a  l  c  o  n  c  e  r  n  s  ,  a  u  t  o  l  o  g  o  u  s  C  B  b  a  n  k  i  n  g  i  n  a  n  a  -p  r  i  o  r  i  h  e  a  l  t  h  y  f  a  m  i  l  y  i  s  c  o  n  t  r  o  v  e  r  s  i  a  l  b  e  c  a  u  s  e  i  t  s  v  a  l  u  e  i  s  n  o  t  e  n  t  i  r  e  l  y  s  u  p  p  o  r  t  e  d  b  y  c  l  i  n  i  c  a  l  e  v  i  d  e  n  c  e  ,  d  e  s  p  i  t  e  w  h  i  c  h  t  h  i  s  h  a  s  d  e  v  e  l  o  p  e  d  i  n  t  o  a  p  r  i  v  a  t  e  i  n  d  u  s  t  r  y  p  r  e  d  o  m  i  n  a  n  t  l  y  u  s  e  d  b  y  e  c  o  n  o  m  i  c  a  l  l  y  a  d  v  a  n  t  a  g  e  d  f  a  m  i  l  i  e  s   1  0  ,  1  1   .  D  i  s  c  u  s  s  i  o  n  a  b  o  u  t  t  h  e  d  e  v  e  l  o  p  m  e  n  t  o  f  h  y  b  r  i  d  C  B  B  m  o  d  e  l  s  t  h  a  t  c  o  u  l  d  c  o  m  b  i  n  e  e  f  f  o  r  t  s  t  o  s  u  p  p  o  r  t  a  l  l  b  a  n  k  i  n  g  a  c  t  i  v  i  t  i  e  s  i  s  t  h  e  s  u  b  j  e  c  t  o  f  i  n  t  e  n  s  e  c  o  n  t  r  o  v  e  r  s  y  b  e  c  a  u  s  e  o  f  e  t  h  i  c  a  l  ,  s  c  i  e  n  t  i  f  i  c  ,  r  e  g  u  l  a  t  o  r  y  ,  e  c  o  n  o  m  i  c  a  n  d  s  o  c  i  a  l  c  o  n  c  e  r  n  s   1  2  ,  1  3 . DOI: 10.3324/haematol.2011.047050 T h  e  c  u  r  r  e  n  t  s  i  t  u  a  t  i  o  n  o  f  f  a  m  i  l  y  -d  i  r  e  c  t  e  d  C  B  t  r  a  n  s  p  l  a  n  t  a  t  i  o  n  a  n  d  b  a  n  k  i  n  g   T  h  e  E  u  r  o  c  o  r  d  r  e  g  i  s  t  r  y  h  a  s  i  d  e  n  t  i  f  i  e  d  5  9  6  p  a  t  i  e  n  t  s  t  r  a  n  s  p  l  a  n  t  e  d  w  i  t  h  r  e  l  a  t  e  d  C  B  f  r  o  m  1  9  8  8  t  o  2  0  1  0  b  u  t  ,  i  n  c  o  n  t  r  a  s  t  t  o  u  n  r  e  l  a  t  e  d  C  B  T  ,  t  h  e  n  u  m  b  e  r  o  f  r  e  l  a  t  e  d  C  B  T  s  h  a  s  n  o  t  i  n  c  r  e  a  s  e  d  y  e  a  r  a  f  t  e  r  y  e  a  r  .  M  o  s  t  r  e  c  i  p  i  e  n  t  s  w  e  r  e  c  h  i  l  d  r  e  n  ,  a  n  d  a  l  l  b  u  t  2  9  w  e  r  e  H  L  A  -m  a  t  c  h  e  d  .  T  h  e  m  a  j  o  r  c  h  a  r  a  c  t  e  r  i  s  t  i  c  s  o  f  t  h  e  p  a  t  i  e  n  t  s  a  n  d  t  r  a  n  s  p  l  a  n  t  s  a  r  e  l  i  s  t  e  d  i  n  T  a  b  l  e  s  1  a  n  d  2  .  4  -y  e  a  r  o  v  e  r  a  l  l  s  u  r  v  i  v  a  l  w  a  s  9  1  %  f  o  r  p  a  t  i  e  n  t  s  w  i  t  h  n  o  n  -m  a  l  i  g  n  a  n  t  d  i  s  e  a  s  e  s  a  n  d  5  6  %  f  o  r  p  a  t  i  e  n  t  s  w  i  t  h  m  a  l  i  g  n  a  n  t  d  i  s  e  a  s  e  s  (  T  a  b  l  e  3  a  n  d  F  i  g  u  r  e  2  )  .  T  h  e  c  u  m  u  l  a  t  i  v  e  i  n  c  i  d  e  n  c  e  (  C  I  )  o  f  n  e  u  t  r  o  p  h  i  l  e  n  g  r  a  f  t  m  e  n  t  w  a  s  9  1  +  3  %  i  n  a  m  e  d  i  a  n  o  f  2  2  d  a  y  s  (  r  a  n  g  e  1  2  -8  0  d  a  y  s  )  .  T  h  e  i  n  c  i  d  e  n  c  e  o  f  a  c  u  t  e  a  n  d  c  h  r  o  n  i  c  G  V  H  D  a  t  d  a  y  1  0  0  a  n  d  a  t  4  y  e  a  r  w  a  s  1  2  +  3  %  a  n  d  1  3  + Grade IV 4 (1%)
Cumulative incidence at day 100 (%) 12±2%
Chronic GVHD 46/451 Limited 38
Extensive 8 Cumulative incidence at 4 years (%) 13±2%
Overall Survival at 4 years (%) 75±2%
Malignant diseases 56±4%, n=188/218
Non-malignant diseases 91±2%, n=259/301
Non relapse mortality at 4 years (%) 8±2%
Cause of death 111
Relapse 62
Transplant-related cause 44
Unknown 5 Acute leukemia, n=4
Immune deficiency, n=3
Thalassemia, n=2
Chronic leukemia, n=1
Fanconi anemia, n=1
Metabolic disease, n=1
Unknown, n=1
France (unpublished data)
Hospital Henri Mondor 111 11 Sickle cell disease, n=9
Thalassemia, n=2 
